Definitive Contract 75N93023C00015
Award Date 7/1/23
Potential Completion Date 6/30/26
Potential Value $4.2M
Federal Agency
Awardee
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
New York, NY 10022, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
16
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,728,096.00 cost-plus-fixed-fee definitive contract to Myelo Therapeutics GmbH, a for-profit limited liability company, for the development of MYELO001 as an orally applied medical countermeasure to treat hematopoietic acute radiation syndrome. This contract, which has a completion date of January 16, 2025, stems from a Broad Agency Announcement seeking proposals to develop safe and effective medical...
- This is a $3,275,826 federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to The Medical College of Wisconsin, Inc. (MCW) to research and develop medical countermeasures and biodosimetry approaches to assess and mitigate acute and delayed radiation injuries. The contract, which has no set-aside designation, is focused on two key goals: 1) developing safe and effective medical countermeasures that can be administered at least 24 hours after radiation...
- This is a $4,879,349 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Chromologic LLC, a minority-owned small business located in Monrovia, California. The contract is for the research and development of biodosimetry approaches and medical countermeasures to assess and mitigate acute or delayed radiation injuries. This work supports NIAID's goals of developing safe and effective countermeasures to reduce radiation-associated mortality...
- This $4,175,467 definitive cost-no-fee contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Pluri Biotech LTD, a for-profit limited liability company based in Israel, for the development of PLX-R18 cell therapy as a countermeasure for hematopoietic acute radiation syndrome. The contract, which has no set-aside designation, supports research and development efforts focused on creating safe and effective medical countermeasures to mitigate...
- This is a $81,904,328.96 cost-no-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to the University of Maryland, Baltimore (UMB) for radiation/nuclear medical countermeasure product development support services. The contract supports the development of medical countermeasures against radiation and nuclear threats, which aligns with NIAID's mission to conduct and support research to...
- This is a cost-plus-fixed-fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to SRI International, a non-profit research and development institute. The contract is for $6,245,298.00 to provide radiation/nuclear medical countermeasure (MCM) product development support services, specifically animal model development and initial efficacy testing of candidate MCMs. This task order is part...
- This is a $36,967,744.00 cost-plus-fixed-fee definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Asell, LLC for the advanced development, validation, and FDA clearance of the CellRadX point-of-care biodosimetry system. The contract is not set-aside. This contract was awarded under a Broad Agency Announcement (BAA) solicitation from the Biomedical Advanced Research and Development Authority (BARDA) seeking proposals for the advanced...
- <p>This is a cost-plus-fixed-fee contract awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to RxBio, Inc., a for-profit organization, for the IND-enabling development of RX100 as a medical countermeasure for gastrointestinal acute radiation syndrome. The contract has a potential value of $4,591,511.92 and a completion date of October 31, 2022. The contract was not set aside for any specific business type.</p>
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $31,725,938.61 cost-plus-fixed-fee contract to Revagenix Inc. to select a novel small molecule antibiotic for clinical development and advance it through IND filing and Phase 1 clinical studies. This contract was not set aside and has an ultimate completion date of August 31, 2026. The contract originated from a NIAID Broad Agency Announcement seeking proposals to develop medical countermeasures to mitigate and/or...
- This federal contract award to Chromologic LLC, a minority-owned small business, was issued by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) for the "Development of Second-Generation Probiotics as Radiation Mitigators." The $2,709,458.08 cost-plus-fixed-fee contract has a 5-year period of performance through March 2026. The contract supports research and development of advanced therapeutic approaches, including...